Coronary interventions

Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study

EuroIntervention 2015;11:555-563 published online ahead of print December 2014. DOI: 10.4244/EIJY14M12_07

Beatriz Vaquerizo1*, MD; Antonio Barros1, MD; Sandra Pujadas1, MD; Ester Bajo1, NP; Darlene Estrada1, MD; F. Miranda-Guardiola2, MD; Juan Rigla3, MD, PhD; Marcelo Jiménez1, MD; Juan Cinca1, MD; Antonio Serra1, MD

1. Cardiology Department, Hospital Sant Pau, Barcelona, Spain; 2. Interventional Cardiology Unit, Hospital del Mar, Barcelona, Spain; 3. Perceptual Computing Lab, Faculty of Mathematics, University of Barcelona, Barcelona, Spain

Aims: We sought to assess the safety and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) in percutaneous chronic total occlusion (CTO) revascularisation

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bioresorbable vascular scaffoldchronic total occlusionplaque modification

Share on Facebook Share on Twitter Share on Linkedin